Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disorder characterized by the destruction of red blood cells. It accounts for approximately 38 cases per million individuals, with an incidence of 0.08-0.57 per 100,000 person-years. According to the paroxysmal nocturnal hemoglobinuria pipeline analysis by Expert Market Research, the therapeutic landscape is evolving with a growing focus on complement inhibitors and gene-based therapies. Rising investments in rare disease research and increasing regulatory support are fueling the development of PNH therapeutics. The market is projected to witness steady growth in the coming years with the launch of novel targeted treatments.
Major companies involved in the paroxysmal nocturnal hemoglobinuria pipeline analysis include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, and others.
Leading drugs currently in the pipeline include HSK39297, BCX9930, and others.
Increased R&D funding, clinical advancements in complement pathway inhibitors, and accelerated regulatory approvals are driving robust growth in the paroxysmal nocturnal hemoglobinuria drug pipeline.
The Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis Report by Expert Market Research gives comprehensive insights into paroxysmal nocturnal hemoglobinuria therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for paroxysmal nocturnal hemoglobinuria. The paroxysmal nocturnal hemoglobinuria report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The paroxysmal nocturnal hemoglobinuria pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with paroxysmal nocturnal hemoglobinuria treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to paroxysmal nocturnal hemoglobinuria.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired blood disorder caused by a mutation in the PIGA gene, leading to the destruction of red blood cells by the immune system. It occurs when the body lacks protective proteins on blood cells, making them vulnerable to complement-mediated attacks, especially at night, resulting in anemia, fatigue, and blood clots.
Paroxysmal nocturnal hemoglobinuria treatment includes complement inhibitors such as eculizumab or ravulizumab, and the recently approved oral therapy, iptacopan, which helps prevent red blood cell destruction and reduces transfusion dependence. In March 2024, the U.S. Food and Drug Administration approved iptacopan, a factor B inhibitor, as the first oral monotherapy for paroxysmal nocturnal hemoglobinuria, offering effective control of anemia and reduced need for transfusions.
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder with an incidence ranging from 0.08 to 0.57 per 100,000 person-years and a prevalence of approximately 38 cases per million individuals. Most cases are identified in early to mid-adulthood, with a median diagnostic age of 35 to 40 years. The PNH drug pipeline focuses on addressing intravascular hemolysis, thrombosis, and bone marrow failure through novel targeted therapies
This section of the report covers the analysis of paroxysmal nocturnal hemoglobinuria drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The paroxysmal nocturnal hemoglobinuria pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total paroxysmal nocturnal hemoglobinuria clinical trials at 50%, highlighting significant ongoing research efforts. Phase III follows with 40%, indicating promising advancements toward late-stage development. Phase I accounts for 13%, reflecting steady early-phase innovation. The strong presence is expected to positively impact the paroxysmal nocturnal hemoglobinuria treatment market by accelerating the development of effective therapies.
The drug molecule categories covered under the paroxysmal nocturnal hemoglobinuria pipeline analysis include peptides, monoclonal antibody, polymer, gene therapy, and small molecule. The paroxysmal nocturnal hemoglobinuria report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for paroxysmal nocturnal hemoglobinuria. Complement inhibitors are a major drug class in the paroxysmal nocturnal hemoglobinuria (PNH) treatment pipeline. For example, Fabhalta (iptacopan), an oral Factor B inhibitor, has demonstrated improved hemoglobin levels in patients previously treated with anti-C5 therapies. This therapy targets the alternative complement pathway, offering a more convenient and effective treatment option for managing PNH-related hemolysis.
The EMR report for the paroxysmal nocturnal hemoglobinuria pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed paroxysmal nocturnal hemoglobinuria therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in paroxysmal nocturnal hemoglobinuria clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for paroxysmal nocturnal hemoglobinuria. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of paroxysmal nocturnal hemoglobinuria drug candidates.
HSK39297, developed by Haisco Pharmaceutical Group Co., Ltd., is currently undergoing a Phase III trial to assess its efficacy and safety in patients with paroxysmal nocturnal hemoglobinuria who are naive to complement inhibitor therapy. As a novel complement factor B inhibitor, HSK39297 aims to provide targeted inhibition of the alternative complement pathway, offering a potential alternative to eculizumab.
BCX9930, an oral Factor D inhibitor developed by BioCryst Pharmaceuticals, is currently undergoing a Phase 2 study for paroxysmal nocturnal hemoglobinuria. This study aims to assess the long-term safety of BCX9930 monotherapy in participants previously treated in BioCryst-sponsored trials. It is providing continued treatment access to eligible individuals lacking alternative options
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for paroxysmal nocturnal hemoglobinuria. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into paroxysmal nocturnal hemoglobinuria collaborations, regulatory environments, and potential growth opportunities.
Warm Autoimmune Hemolytic Anemia Market Report and Forecast
Warm Autoimmune Hemolytic Anemia Pipeline Analysis Report
Warm Autoimmune Hemolytic Anemia (wAIHA) Epidemiology Forecast
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share